TriangleLABELS · 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
INFLECTRA
Open original source → · Download preserved record
Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.
- Label effective date
- 2026-07-28
- Captured
- 2026-09-09T23:37:42.544548+00:00
- Current indication reconciliation
- Not reconciled
Boxed warning in this label
- WARNING: SERIOUS INFECTIONS and MALIGNANCY WARNING: SERIOUS INFECTIONS and MALIGNANCY See full prescribing information for complete boxed warning • Increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis) and infections due to other opportunistic pathogens. ( 5.1 ) • Discontinue INFLECTRA if a patient develops a serious infection. • Perform test for latent TB; if positive, start treatment for TB prior to starting INFLECTRA. Monitor all patients for active TB during treatment, even if initial latent TB test is negative. ( 5.1 ) • Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with tumor necrosis factor (TNF) blockers, including infliximab products. ( 5.2 ) • Postmarketing cases of fatal hepatosplenic T-cell lymphoma (HSTCL) have been reported in patients treated with TNF blockers, including infliximab products. Almost all had received azathioprine or 6-mercaptopurine concomitantly with a TNF blocker at or prior to diagnosis. The majority of cases were reported in patients with Crohn's disease or ulcerative colitis, most of whom were adolescent or young adult males. ( 5.2 ) SERIOUS INFECTIONS Patients treated with infliximab products are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions (5.1) , Adverse Reactions (6.1) ]. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. INFLECTRA should be discontinued if a patient develops a serious infection or sepsis. Reported infections include: • Active tuberculosis, including reactivation of latent tuberculosis. Patients with tuberculosis have frequently presented with disseminated or extrapulmonary disease. Patients should be tested for latent tuberculosis before INFLECTRA use and during therapy. Treatment for latent infection should be initiated prior to INFLECTRA use. • Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Empiric anti-fungal therapy should be considered in patients at risk for invasive fungal infections who develop severe systemic illness. • Bacterial, viral and other infections due to opportunistic pathogens, including Legionella and Listeria. The risks and benefits of treatment with INFLECTRA should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection. Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with INFLECTRA, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy. MALIGNANCY Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, including infliximab products [see Warnings and Precautions (5.2) ] . Postmarketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have been reported in patients treated with TNF blockers including infliximab products. These cases have had a very aggressive disease course and have been fatal. Almost all patients had received treatment with azathioprine or 6-mercaptopurine concomitantly with a TNF blocker at or prior to diagnosis. The majority of reported cases have occurred in patients with Crohn's disease or ulcerative colitis and most were in adolescent and young adult males.
Indications and usage: exact source text
- 1 INDICATIONS AND USAGE INFLECTRA is a tumor necrosis factor (TNF) blocker indicated for: Crohn's Disease ( 1.1 ): • reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. • reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing disease. Pediatric Crohn's Disease ( 1.2 ): • reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active disease who have had an inadequate response to conventional therapy. Ulcerative Colitis ( 1.3 ): • reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. Pediatric Ulcerative Colitis ( 1.4 ): • reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active disease who have had an inadequate response to conventional therapy. Rheumatoid Arthritis ( 1.5 ) in combination with methotrexate: • reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active disease. Ankylosing Spondylitis ( 1.6 ): • reducing signs and symptoms in adult patients with active disease. Psoriatic Arthritis ( 1.7 ): • reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in adult patients. Plaque Psoriasis ( 1.8 ): • treatment of adult patients with chronic severe (i.e., extensive and/or disabling) plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate. 1.1 Crohn's Disease INFLECTRA is indicated for: • reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn's disease (CD) who have had an inadequate response to conventional therapy. • reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing CD. 1.2 Pediatric Crohn's Disease INFLECTRA is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active CD who have had an inadequate response to conventional therapy. 1.3 Ulcerative Colitis INFLECTRA is indicated for reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to conventional therapy. 1.4 Pediatric Ulcerative Colitis INFLECTRA is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active UC who have had an inadequate response to conventional therapy. 1.5 Rheumatoid Arthritis INFLECTRA, in combination with methotrexate, is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis (RA). 1.6 Ankylosing Spondylitis INFLECTRA is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis (AS). 1.7 Psoriatic Arthritis INFLECTRA is indicated for reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in adult patients with psoriatic arthritis (PsA). 1.8 Plaque Psoriasis INFLECTRA is indicated for the treatment of adult patients with chronic severe (i.e., extensive and/or disabling) plaque psoriasis (Ps) who are candidates for systemic therapy and when other systemic therapies are medically less appropriate. INFLECTRA should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician [see Boxed Warning , Warnings and Precautions (5) ] .
Full extracted label fields
- application numbers
- BLA125544
- boxed warning exact
- WARNING: SERIOUS INFECTIONS and MALIGNANCY WARNING: SERIOUS INFECTIONS and MALIGNANCY See full prescribing information for complete boxed warning • Increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis) and infections due to other opportunistic pathogens. ( 5.1 ) • Discontinue INFLECTRA if a patient develops a serious infection. • Perform test for latent TB; if positive, start treatment for TB prior to starting INFLECTRA. Monitor all patients for active TB during treatment, even if initial latent TB test is negative. ( 5.1 ) • Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with tumor necrosis factor (TNF) blockers, including infliximab products. ( 5.2 ) • Postmarketing cases of fatal hepatosplenic T-cell lymphoma (HSTCL) have been reported in patients treated with TNF blockers, including infliximab products. Almost all had received azathioprine or 6-mercaptopurine concomitantly with a TNF blocker at or prior to diagnosis. The majority of cases were reported in patients with Crohn's disease or ulcerative colitis, most of whom were adolescent or young adult males. ( 5.2 ) SERIOUS INFECTIONS Patients treated with infliximab products are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions (5.1) , Adverse Reactions (6.1) ]. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. INFLECTRA should be discontinued if a patient develops a serious infection or sepsis. Reported infections include: • Active tuberculosis, including reactivation of latent tuberculosis. Patients with tuberculosis have frequently presented with disseminated or extrapulmonary disease. Patients should be tested for latent tuberculosis before INFLECTRA use and during therapy. Treatment for latent infection should be initiated prior to INFLECTRA use. • Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Empiric anti-fungal therapy should be considered in patients at risk for invasive fungal infections who develop severe systemic illness. • Bacterial, viral and other infections due to opportunistic pathogens, including Legionella and Listeria. The risks and benefits of treatment with INFLECTRA should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection. Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with INFLECTRA, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy. MALIGNANCY Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, including infliximab products [see Warnings and Precautions (5.2) ] . Postmarketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have been reported in patients treated with TNF blockers including infliximab products. These cases have had a very aggressive disease course and have been fatal. Almost all patients had received treatment with azathioprine or 6-mercaptopurine concomitantly with a TNF blocker at or prior to diagnosis. The majority of reported cases have occurred in patients with Crohn's disease or ulcerative colitis and most were in adolescent and young adult males.
- brand names
- INFLECTRA
- current indication status
- not_reconciled
- dailymed set url
- https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=37eaca10-d812-48bc-8b8e-b836bfa9968f
- generic names
- INFLIXIMAB-DYYB
- id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- indications and usage exact
- 1 INDICATIONS AND USAGE INFLECTRA is a tumor necrosis factor (TNF) blocker indicated for: Crohn's Disease ( 1.1 ): • reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. • reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing disease. Pediatric Crohn's Disease ( 1.2 ): • reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active disease who have had an inadequate response to conventional therapy. Ulcerative Colitis ( 1.3 ): • reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. Pediatric Ulcerative Colitis ( 1.4 ): • reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active disease who have had an inadequate response to conventional therapy. Rheumatoid Arthritis ( 1.5 ) in combination with methotrexate: • reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active disease. Ankylosing Spondylitis ( 1.6 ): • reducing signs and symptoms in adult patients with active disease. Psoriatic Arthritis ( 1.7 ): • reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in adult patients. Plaque Psoriasis ( 1.8 ): • treatment of adult patients with chronic severe (i.e., extensive and/or disabling) plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate. 1.1 Crohn's Disease INFLECTRA is indicated for: • reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn's disease (CD) who have had an inadequate response to conventional therapy. • reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing CD. 1.2 Pediatric Crohn's Disease INFLECTRA is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active CD who have had an inadequate response to conventional therapy. 1.3 Ulcerative Colitis INFLECTRA is indicated for reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to conventional therapy. 1.4 Pediatric Ulcerative Colitis INFLECTRA is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active UC who have had an inadequate response to conventional therapy. 1.5 Rheumatoid Arthritis INFLECTRA, in combination with methotrexate, is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis (RA). 1.6 Ankylosing Spondylitis INFLECTRA is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis (AS). 1.7 Psoriatic Arthritis INFLECTRA is indicated for reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in adult patients with psoriatic arthritis (PsA). 1.8 Plaque Psoriasis INFLECTRA is indicated for the treatment of adult patients with chronic severe (i.e., extensive and/or disabling) plaque psoriasis (Ps) who are candidates for systemic therapy and when other systemic therapies are medically less appropriate. INFLECTRA should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician [see Boxed Warning , Warnings and Precautions (5) ] .
- indications and usage tables exact
- is original packager
- true
- manufacturer names
- Pfizer Laboratories Div Pfizer Inc
- matched search terms
- tumor
- package ndcs
- 0069-0809-01
- product ndcs
- 0069-0809
- product types
- HUMAN PRESCRIPTION DRUG
- recent major changes exact
- record type
- complete_spl_indications_section_candidate
- routes
- INTRAVENOUS
- rxcuis
- 1790541
- 1790546
- source batch
- file
- /private/tmp/cancer-full-research/indications/raw/labels-00100.json
- meta
- disclaimer
- Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
- last updated
- 2026-09-09
- results
- limit
- 100
- skip
- 100
- total
- 830
- sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22248ec8d1-8b3d-480f-8cdc-dbda1f130d17%22
- spl effective date
- 2026-07-28
- spl effective time
- 20260728
- spl set id
- 37eaca10-d812-48bc-8b8e-b836bfa9968f
- spl version
- 24
- substance names
- INFLIXIMAB
- uniis
- B72HH48FLU
- verification flags
- oncology_keyword_candidate_not_clinically_classified
- spl_text_not_verified_identical_to_latest_approved_label
- individual_indications_not_split_or_reconciled
Drugs@FDA application source records
- application number
- BLA125544
- payload
- all indexed label documents
- Appl No
- 125544
- Application Docs Date
- 2016-04-05 00:00:00
- Application Docs ID
- 18933
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125544s000lbl.pdf
- Submission No
- 1
- Submission Type
- ORIG
- Appl No
- 125544
- Application Docs Date
- 2019-03-07 00:00:00
- Application Docs ID
- 57921
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125544s008lbl.pdf
- Submission No
- 8
- Submission Type
- SUPPL
- Appl No
- 125544
- Application Docs Date
- 2019-06-20 00:00:00
- Application Docs ID
- 59140
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125544s009lbl.pdf
- Submission No
- 9
- Submission Type
- SUPPL
- Appl No
- 125544
- Application Docs Date
- 2021-06-24 00:00:00
- Application Docs ID
- 67882
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125544s018lbl.pdf
- Submission No
- 18
- Submission Type
- SUPPL
- Appl No
- 125544
- Application Docs Date
- 2025-09-05 00:00:00
- Application Docs ID
- 83298
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125544s055lbl.pdf
- Submission No
- 55
- Submission Type
- SUPPL
- all submission records
- Appl No
- 125544
- Review Priority
- STANDARD
- Submission Class Code ID
- 9
- Submission No
- 1
- Submission Status
- AP
- Submission Status Date
- 2016-04-05 00:00:00
- Submission Type
- ORIG
- Submissions Public Notes
- Appl No
- 125544
- Review Priority
- STANDARD
- Submission Class Code ID
- 3
- Submission No
- 8
- Submission Status
- AP
- Submission Status Date
- 2018-07-27 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 125544
- Review Priority
- STANDARD
- Submission Class Code ID
- 2
- Submission No
- 9
- Submission Status
- AP
- Submission Status Date
- 2019-06-18 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 125544
- Review Priority
- STANDARD
- Submission Class Code ID
- 3
- Submission No
- 18
- Submission Status
- AP
- Submission Status Date
- 2021-06-17 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 125544
- Review Priority
- Submission Class Code ID
- 28
- Submission No
- 55
- Submission Status
- AP
- Submission Status Date
- 2025-09-03 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- application number
- BLA125544
- approval interpretation
- Application linkage and approved submission are not indication-level current approval verification
- current indication status
- not_reconciled
- drugsfda url
- https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125544
- has approved submission record
- true
- latest approved submission date
- 2025-09-03
- latest label selection rule
- max FDA ApplicationDocsDate, including all ties; posting date is not approval date and latest indexed document may be incomplete
- latest posted label documents
- Appl No
- 125544
- Application Docs Date
- 2025-09-05 00:00:00
- Application Docs ID
- 83298
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125544s055lbl.pdf
- Submission No
- 55
- Submission Type
- SUPPL
- official application record
- Appl No
- 125544
- Appl Public Notes
- Appl Type
- BLA
- Sponsor Name
- CELLTRION INC
- openfda application present
- true
- products
- Active Ingredient
- INFLIXIMAB-DYYB
- Appl No
- 125544
- Drug Name
- INFLECTRA
- Form
- INJECTABLE;INJECTION
- Product No
- 001
- Reference Drug
- 2
- Reference Standard
- Strength
- 100MG
- marketing status
- Prescription
Source passages and status connections
Passage 1 · indication intro context
- application numbers
- BLA125544
- brand names
- INFLECTRA
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- incomplete_colon_led_indication_intro
- clinical review status
- pending
- content role
- indication_intro_context
- context span
- end
- 314
- end exclusive
- true
- exact text
- 1 INDICATIONS AND USAGE INFLECTRA is a tumor necrosis factor (TNF) blocker indicated for: Crohn's Disease ( 1.1 ): • reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy.
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 0
- current approval status
- not_reconciled
- duplicate text group
- dup-54831d0a411999546d65
- extraction review status
- automated_candidate_pending_source_review
- generic names
- INFLIXIMAB-DYYB
- id
- ind-span-ff5b38dabf97e7c86f78
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- positive predicate support span
- end
- 84
- end exclusive
- true
- exact text
- is a tumor necrosis factor (TNF) blocker indicated
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 34
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- source span
- end
- 114
- end exclusive
- true
- exact text
- 1 INDICATIONS AND USAGE INFLECTRA is a tumor necrosis factor (TNF) blocker indicated for: Crohn's Disease ( 1.1 ):
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 0
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22248ec8d1-8b3d-480f-8cdc-dbda1f130d17%22
- spl effective date
- 2026-07-28
- spl set id
- 37eaca10-d812-48bc-8b8e-b836bfa9968f
- spl version
- 24
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- not_applicable
Passage 2 · positive indication candidate
- application numbers
- BLA125544
- brand names
- INFLECTRA
- classification reasons
- inherited_predicate_from_same_label_section_requires_review
- no_tumor_directed_keyword_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 514
- end exclusive
- true
- exact text
- 1 INDICATIONS AND USAGE INFLECTRA is a tumor necrosis factor (TNF) blocker indicated for: Crohn's Disease ( 1.1 ): • reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. • reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing disease. Pediatric Crohn's Disease ( 1.2 ): • reducing s
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 0
- current approval status
- not_reconciled
- duplicate text group
- dup-8a3cdd27c56f719324c5
- extraction review status
- automated_candidate_pending_source_review
- generic names
- INFLIXIMAB-DYYB
- id
- ind-span-9b8c10d2076891f41603
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- positive predicate support span
- end
- 84
- end exclusive
- true
- exact text
- is a tumor necrosis factor (TNF) blocker indicated
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 34
- qualifier mentions
- context exact
- symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active disease who have had an
- kind
- age
- polarity
- not_inferred
- span
- end
- 210
- end exclusive
- true
- exact text
- adult patients
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 196
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- source span
- end
- 314
- end exclusive
- true
- exact text
- • reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy.
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 115
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22248ec8d1-8b3d-480f-8cdc-dbda1f130d17%22
- spl effective date
- 2026-07-28
- spl set id
- 37eaca10-d812-48bc-8b8e-b836bfa9968f
- spl version
- 24
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- non_oncology_or_unclear_candidate
Passage 3 · positive indication candidate
- application numbers
- BLA125544
- brand names
- INFLECTRA
- classification reasons
- inherited_predicate_from_same_label_section_requires_review
- no_tumor_directed_keyword_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 666
- end exclusive
- true
- exact text
- • reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. • reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing disease. Pediatric Crohn's Disease ( 1.2 ): • reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active dise
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 115
- current approval status
- not_reconciled
- duplicate text group
- dup-6d999dd2934b9354a45d
- extraction review status
- automated_candidate_pending_source_review
- generic names
- INFLIXIMAB-DYYB
- id
- ind-span-9465fa3827dc556dab55
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- positive predicate support span
- end
- 84
- end exclusive
- true
- exact text
- is a tumor necrosis factor (TNF) blocker indicated
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 34
- qualifier mentions
- context exact
- nd rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing disease.
- kind
- age
- polarity
- not_inferred
- span
- end
- 440
- end exclusive
- true
- exact text
- adult patients
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 426
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- source span
- end
- 466
- end exclusive
- true
- exact text
- • reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing disease.
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 315
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22248ec8d1-8b3d-480f-8cdc-dbda1f130d17%22
- spl effective date
- 2026-07-28
- spl set id
- 37eaca10-d812-48bc-8b8e-b836bfa9968f
- spl version
- 24
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- non_oncology_or_unclear_candidate
Passage 4 · unclassified context
- application numbers
- BLA125544
- brand names
- INFLECTRA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 701
- end exclusive
- true
- exact text
- an inadequate response to conventional therapy. • reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing disease. Pediatric Crohn's Disease ( 1.2 ): • reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active disease who have had an inadequate resp
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 267
- current approval status
- not_reconciled
- duplicate text group
- dup-82f6e41edb8c4d228cd0
- extraction review status
- automated_candidate_pending_source_review
- generic names
- INFLIXIMAB-DYYB
- id
- ind-span-f6d4ab68b3afa79aa21f
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- Pediatric Crohn's Disease ( 1.2 ):
- kind
- age
- polarity
- not_inferred
- span
- end
- 476
- end exclusive
- true
- exact text
- Pediatric
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 467
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- source span
- end
- 501
- end exclusive
- true
- exact text
- Pediatric Crohn's Disease ( 1.2 ):
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 467
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22248ec8d1-8b3d-480f-8cdc-dbda1f130d17%22
- spl effective date
- 2026-07-28
- spl set id
- 37eaca10-d812-48bc-8b8e-b836bfa9968f
- spl version
- 24
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 5 · positive indication candidate
- application numbers
- BLA125544
- brand names
- INFLECTRA
- classification reasons
- inherited_predicate_from_same_label_section_requires_review
- no_tumor_directed_keyword_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 930
- end exclusive
- true
- exact text
- nal therapy. • reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing disease. Pediatric Crohn's Disease ( 1.2 ): • reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active disease who have had an inadequate response to conventional therapy. Ulcerative Colitis ( 1.3 ): • reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to sev
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 302
- current approval status
- not_reconciled
- duplicate text group
- dup-0d7eac7435c62d7f79aa
- extraction review status
- automated_candidate_pending_source_review
- generic names
- INFLIXIMAB-DYYB
- id
- ind-span-de3f7e80b229df65d80b
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- positive predicate support span
- end
- 84
- end exclusive
- true
- exact text
- is a tumor necrosis factor (TNF) blocker indicated
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 34
- qualifier mentions
- context exact
- symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active
- kind
- age
- polarity
- not_inferred
- span
- end
- 601
- end exclusive
- true
- exact text
- pediatric patients
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 583
- context exact
- ng and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active disease who ha
- kind
- age
- polarity
- not_inferred
- span
- end
- 616
- end exclusive
- true
- exact text
- 6 years of age
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 602
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- source span
- end
- 730
- end exclusive
- true
- exact text
- • reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active disease who have had an inadequate response to conventional therapy.
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 502
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22248ec8d1-8b3d-480f-8cdc-dbda1f130d17%22
- spl effective date
- 2026-07-28
- spl set id
- 37eaca10-d812-48bc-8b8e-b836bfa9968f
- spl version
- 24
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- non_oncology_or_unclear_candidate
Passage 6 · unclassified context
- application numbers
- BLA125544
- brand names
- INFLECTRA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 958
- end exclusive
- true
- exact text
- and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active disease who have had an inadequate response to conventional therapy. Ulcerative Colitis ( 1.3 ): • reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active disease who hav
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 531
- current approval status
- not_reconciled
- duplicate text group
- dup-e87a021a1ed378231d14
- extraction review status
- automated_candidate_pending_source_review
- generic names
- INFLIXIMAB-DYYB
- id
- ind-span-f9ced3be5f1bfba43a2e
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- source span
- end
- 758
- end exclusive
- true
- exact text
- Ulcerative Colitis ( 1.3 ):
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 731
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22248ec8d1-8b3d-480f-8cdc-dbda1f130d17%22
- spl effective date
- 2026-07-28
- spl set id
- 37eaca10-d812-48bc-8b8e-b836bfa9968f
- spl version
- 24
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 7 · unclassified context
- application numbers
- BLA125544
- brand names
- INFLECTRA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1211
- end exclusive
- true
- exact text
- g clinical remission in pediatric patients 6 years of age and older with moderately to severely active disease who have had an inadequate response to conventional therapy. Ulcerative Colitis ( 1.3 ): • reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. Pediatric Ulcerative Colitis ( 1.4 ): • reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active d
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 559
- current approval status
- not_reconciled
- duplicate text group
- dup-01ce7c998efcfd86318e
- extraction review status
- automated_candidate_pending_source_review
- generic names
- INFLIXIMAB-DYYB
- id
- ind-span-b4ae97d3458aa3d337a4
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active disease who have had an
- kind
- age
- polarity
- not_inferred
- span
- end
- 907
- end exclusive
- true
- exact text
- adult patients
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 893
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- source span
- end
- 1011
- end exclusive
- true
- exact text
- • reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy.
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 759
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22248ec8d1-8b3d-480f-8cdc-dbda1f130d17%22
- spl effective date
- 2026-07-28
- spl set id
- 37eaca10-d812-48bc-8b8e-b836bfa9968f
- spl version
- 24
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 8 · unclassified context
- application numbers
- BLA125544
- brand names
- INFLECTRA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1249
- end exclusive
- true
- exact text
- ng clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. Pediatric Ulcerative Colitis ( 1.4 ): • reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active disease who have had an inadequate resp
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 812
- current approval status
- not_reconciled
- duplicate text group
- dup-c0907da5c5993908f010
- extraction review status
- automated_candidate_pending_source_review
- generic names
- INFLIXIMAB-DYYB
- id
- ind-span-53ff6ee71c18a8923e7d
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- Pediatric Ulcerative Colitis ( 1.4 ):
- kind
- age
- polarity
- not_inferred
- span
- end
- 1021
- end exclusive
- true
- exact text
- Pediatric
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 1012
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- source span
- end
- 1049
- end exclusive
- true
- exact text
- Pediatric Ulcerative Colitis ( 1.4 ):
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 1012
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22248ec8d1-8b3d-480f-8cdc-dbda1f130d17%22
- spl effective date
- 2026-07-28
- spl set id
- 37eaca10-d812-48bc-8b8e-b836bfa9968f
- spl version
- 24
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 9 · unclassified context
- application numbers
- BLA125544
- brand names
- INFLECTRA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1478
- end exclusive
- true
- exact text
- ing, and eliminating corticosteroid use in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. Pediatric Ulcerative Colitis ( 1.4 ): • reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active disease who have had an inadequate response to conventional therapy. Rheumatoid Arthritis ( 1.5 ) in combination with methotrexate: • reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with m
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 850
- current approval status
- not_reconciled
- duplicate text group
- dup-0d7eac7435c62d7f79aa
- extraction review status
- automated_candidate_pending_source_review
- generic names
- INFLIXIMAB-DYYB
- id
- ind-span-5591ee524b6aee50ed2e
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active
- kind
- age
- polarity
- not_inferred
- span
- end
- 1149
- end exclusive
- true
- exact text
- pediatric patients
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 1131
- context exact
- ng and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active disease who ha
- kind
- age
- polarity
- not_inferred
- span
- end
- 1164
- end exclusive
- true
- exact text
- 6 years of age
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 1150
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- source span
- end
- 1278
- end exclusive
- true
- exact text
- • reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active disease who have had an inadequate response to conventional therapy.
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 1050
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22248ec8d1-8b3d-480f-8cdc-dbda1f130d17%22
- spl effective date
- 2026-07-28
- spl set id
- 37eaca10-d812-48bc-8b8e-b836bfa9968f
- spl version
- 24
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 10 · unclassified context
- application numbers
- BLA125544
- brand names
- INFLECTRA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1507
- end exclusive
- true
- exact text
- and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active disease who have had an inadequate response to conventional therapy. Rheumatoid Arthritis ( 1.5 ) in combination with methotrexate: • reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 1079
- current approval status
- not_reconciled
- duplicate text group
- dup-d51b7851fd47eb40a439
- extraction review status
- automated_candidate_pending_source_review
- generic names
- INFLIXIMAB-DYYB
- id
- ind-span-86796f58603933f9b6a1
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- source span
- end
- 1307
- end exclusive
- true
- exact text
- Rheumatoid Arthritis ( 1.5 )
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 1279
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22248ec8d1-8b3d-480f-8cdc-dbda1f130d17%22
- spl effective date
- 2026-07-28
- spl set id
- 37eaca10-d812-48bc-8b8e-b836bfa9968f
- spl version
- 24
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 11 · unclassified context
- application numbers
- BLA125544
- brand names
- INFLECTRA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1541
- end exclusive
- true
- exact text
- clinical remission in pediatric patients 6 years of age and older with moderately to severely active disease who have had an inadequate response to conventional therapy. Rheumatoid Arthritis ( 1.5 ) in combination with methotrexate: • reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active disease. Ankylosing Spondylitis (
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 1108
- current approval status
- not_reconciled
- duplicate text group
- dup-c9e8be9063d1f732e5f1
- extraction review status
- automated_candidate_pending_source_review
- generic names
- INFLIXIMAB-DYYB
- id
- ind-span-1d62e66d10082e5806b1
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- in combination with methotrexate:
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 1341
- end exclusive
- true
- exact text
- methotrexate:
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 1328
- context exact
- in combination with methotrexate:
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 1341
- end exclusive
- true
- exact text
- in combination with methotrexate:
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 1308
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- source span
- end
- 1341
- end exclusive
- true
- exact text
- in combination with methotrexate:
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 1308
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22248ec8d1-8b3d-480f-8cdc-dbda1f130d17%22
- spl effective date
- 2026-07-28
- spl set id
- 37eaca10-d812-48bc-8b8e-b836bfa9968f
- spl version
- 24
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 12 · unclassified context
- application numbers
- BLA125544
- brand names
- INFLECTRA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1715
- end exclusive
- true
- exact text
- atients 6 years of age and older with moderately to severely active disease who have had an inadequate response to conventional therapy. Rheumatoid Arthritis ( 1.5 ) in combination with methotrexate: • reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active disease. Ankylosing Spondylitis ( 1.6 ): • reducing signs and symptoms in adult patients with active disease. Psoriatic Arthritis ( 1.7 ): • reducing signs and symptoms of active arthritis, inhibiting the pro
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 1142
- current approval status
- not_reconciled
- duplicate text group
- dup-673970a472722571274c
- extraction review status
- automated_candidate_pending_source_review
- generic names
- INFLIXIMAB-DYYB
- id
- ind-span-0baa7db93e3fc5ca1d8f
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- on of structural damage, and improving physical function in adult patients with moderately to severely active disease.
- kind
- age
- polarity
- not_inferred
- span
- end
- 1471
- end exclusive
- true
- exact text
- adult patients
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 1457
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- source span
- end
- 1515
- end exclusive
- true
- exact text
- • reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active disease.
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 1342
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22248ec8d1-8b3d-480f-8cdc-dbda1f130d17%22
- spl effective date
- 2026-07-28
- spl set id
- 37eaca10-d812-48bc-8b8e-b836bfa9968f
- spl version
- 24
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 13 · unclassified context
- application numbers
- BLA125544
- brand names
- INFLECTRA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1747
- end exclusive
- true
- exact text
- nation with methotrexate: • reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active disease. Ankylosing Spondylitis ( 1.6 ): • reducing signs and symptoms in adult patients with active disease. Psoriatic Arthritis ( 1.7 ): • reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, a
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 1316
- current approval status
- not_reconciled
- duplicate text group
- dup-464f5b476d4db3b45f88
- extraction review status
- automated_candidate_pending_source_review
- generic names
- INFLIXIMAB-DYYB
- id
- ind-span-5187f759f9033f11f1cd
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- source span
- end
- 1547
- end exclusive
- true
- exact text
- Ankylosing Spondylitis ( 1.6 ):
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 1516
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22248ec8d1-8b3d-480f-8cdc-dbda1f130d17%22
- spl effective date
- 2026-07-28
- spl set id
- 37eaca10-d812-48bc-8b8e-b836bfa9968f
- spl version
- 24
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 14 · unclassified context
- application numbers
- BLA125544
- brand names
- INFLECTRA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1816
- end exclusive
- true
- exact text
- cing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active disease. Ankylosing Spondylitis ( 1.6 ): • reducing signs and symptoms in adult patients with active disease. Psoriatic Arthritis ( 1.7 ): • reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in adult patients. Plaque Psoriasis (
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 1348
- current approval status
- not_reconciled
- duplicate text group
- dup-e52ba1460b545f560e4e
- extraction review status
- automated_candidate_pending_source_review
- generic names
- INFLIXIMAB-DYYB
- id
- ind-span-5920df51ac6b1a14bb9b
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • reducing signs and symptoms in adult patients with active disease.
- kind
- age
- polarity
- not_inferred
- span
- end
- 1595
- end exclusive
- true
- exact text
- adult patients
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 1581
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- source span
- end
- 1616
- end exclusive
- true
- exact text
- • reducing signs and symptoms in adult patients with active disease.
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 1548
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22248ec8d1-8b3d-480f-8cdc-dbda1f130d17%22
- spl effective date
- 2026-07-28
- spl set id
- 37eaca10-d812-48bc-8b8e-b836bfa9968f
- spl version
- 24
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 15 · unclassified context
- application numbers
- BLA125544
- brand names
- INFLECTRA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1845
- end exclusive
- true
- exact text
- age, and improving physical function in adult patients with moderately to severely active disease. Ankylosing Spondylitis ( 1.6 ): • reducing signs and symptoms in adult patients with active disease. Psoriatic Arthritis ( 1.7 ): • reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in adult patients. Plaque Psoriasis ( 1.8 ): • treatment of adult p
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 1417
- current approval status
- not_reconciled
- duplicate text group
- dup-c45385366a99b678b1d6
- extraction review status
- automated_candidate_pending_source_review
- generic names
- INFLIXIMAB-DYYB
- id
- ind-span-0e7aa0b2aafaa9b10f9f
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- source span
- end
- 1645
- end exclusive
- true
- exact text
- Psoriatic Arthritis ( 1.7 ):
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 1617
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22248ec8d1-8b3d-480f-8cdc-dbda1f130d17%22
- spl effective date
- 2026-07-28
- spl set id
- 37eaca10-d812-48bc-8b8e-b836bfa9968f
- spl version
- 24
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 16 · unclassified context
- application numbers
- BLA125544
- brand names
- INFLECTRA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1996
- end exclusive
- true
- exact text
- unction in adult patients with moderately to severely active disease. Ankylosing Spondylitis ( 1.6 ): • reducing signs and symptoms in adult patients with active disease. Psoriatic Arthritis ( 1.7 ): • reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in adult patients. Plaque Psoriasis ( 1.8 ): • treatment of adult patients with chronic severe (i.e., extensive and/or disabling) plaque psoriasis who are candidates for systemic therapy and when other systemic therapi
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 1446
- current approval status
- not_reconciled
- duplicate text group
- dup-52c720082f4b032752d3
- extraction review status
- automated_candidate_pending_source_review
- generic names
- INFLIXIMAB-DYYB
- id
- ind-span-bb85fa3c60b640637ba5
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- on of structural damage, and improving physical function in adult patients.
- kind
- age
- polarity
- not_inferred
- span
- end
- 1795
- end exclusive
- true
- exact text
- adult patients
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 1781
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- source span
- end
- 1796
- end exclusive
- true
- exact text
- • reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in adult patients.
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 1646
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22248ec8d1-8b3d-480f-8cdc-dbda1f130d17%22
- spl effective date
- 2026-07-28
- spl set id
- 37eaca10-d812-48bc-8b8e-b836bfa9968f
- spl version
- 24
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 17 · unclassified context
- application numbers
- BLA125544
- brand names
- INFLECTRA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 2022
- end exclusive
- true
- exact text
- ith active disease. Psoriatic Arthritis ( 1.7 ): • reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in adult patients. Plaque Psoriasis ( 1.8 ): • treatment of adult patients with chronic severe (i.e., extensive and/or disabling) plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appr
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 1597
- current approval status
- not_reconciled
- duplicate text group
- dup-6f4ef2c3f8e1bd4c472e
- extraction review status
- automated_candidate_pending_source_review
- generic names
- INFLIXIMAB-DYYB
- id
- ind-span-18bb82669da77b83e29c
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- source span
- end
- 1822
- end exclusive
- true
- exact text
- Plaque Psoriasis ( 1.8 ):
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 1797
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22248ec8d1-8b3d-480f-8cdc-dbda1f130d17%22
- spl effective date
- 2026-07-28
- spl set id
- 37eaca10-d812-48bc-8b8e-b836bfa9968f
- spl version
- 24
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 18 · unclassified context
- application numbers
- BLA125544
- brand names
- INFLECTRA
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 2230
- end exclusive
- true
- exact text
- tic Arthritis ( 1.7 ): • reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in adult patients. Plaque Psoriasis ( 1.8 ): • treatment of adult patients with chronic severe (i.e., extensive and/or disabling) plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate. 1.1 Crohn's Disease INFLECTRA is indicated for: • reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn's disease (CD)
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 1623
- current approval status
- not_reconciled
- duplicate text group
- dup-9fa08dc5486175bc7a37
- extraction review status
- automated_candidate_pending_source_review
- generic names
- INFLIXIMAB-DYYB
- id
- ind-span-2d448fd36731f6d37516
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • treatment of adult patients with chronic severe (i.e., extensive and/or disabling) plaq
- kind
- age
- polarity
- not_inferred
- span
- end
- 1852
- end exclusive
- true
- exact text
- adult patients
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 1838
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- source span
- end
- 2030
- end exclusive
- true
- exact text
- • treatment of adult patients with chronic severe (i.e., extensive and/or disabling) plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate.
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 1823
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22248ec8d1-8b3d-480f-8cdc-dbda1f130d17%22
- spl effective date
- 2026-07-28
- spl set id
- 37eaca10-d812-48bc-8b8e-b836bfa9968f
- spl version
- 24
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 19 · indication intro context
- application numbers
- BLA125544
- brand names
- INFLECTRA
- classification reasons
- explicit_positive_indication_predicate
- no_tumor_directed_keyword_in_positive_statement
- incomplete_colon_led_indication_intro
- clinical review status
- pending
- content role
- indication_intro_context
- context span
- end
- 2278
- end exclusive
- true
- exact text
- ent of adult patients with chronic severe (i.e., extensive and/or disabling) plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate. 1.1 Crohn's Disease INFLECTRA is indicated for: • reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn's disease (CD) who have had an inadequate response to conventi
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 1831
- current approval status
- not_reconciled
- duplicate text group
- dup-139a65954d01522d2483
- extraction review status
- automated_candidate_pending_source_review
- generic names
- INFLIXIMAB-DYYB
- id
- ind-span-4bdefff382edef1ba0df
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- positive predicate support span
- end
- 2073
- end exclusive
- true
- exact text
- is indicated
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 2061
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- source span
- end
- 2078
- end exclusive
- true
- exact text
- 1.1 Crohn's Disease INFLECTRA is indicated for:
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 2031
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22248ec8d1-8b3d-480f-8cdc-dbda1f130d17%22
- spl effective date
- 2026-07-28
- spl set id
- 37eaca10-d812-48bc-8b8e-b836bfa9968f
- spl version
- 24
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- not_applicable
Passage 20 · positive indication candidate
- application numbers
- BLA125544
- brand names
- INFLECTRA
- classification reasons
- inherited_predicate_from_same_label_section_requires_review
- no_tumor_directed_keyword_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 2491
- end exclusive
- true
- exact text
- extensive and/or disabling) plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate. 1.1 Crohn's Disease INFLECTRA is indicated for: • reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn's disease (CD) who have had an inadequate response to conventional therapy. • reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing CD. 1.2 Pediatric Crohn's Disease INFLECTRA is indicated
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 1879
- current approval status
- not_reconciled
- duplicate text group
- dup-799256ee142df1895faa
- extraction review status
- automated_candidate_pending_source_review
- generic names
- INFLIXIMAB-DYYB
- id
- ind-span-4fde6db274a3e44445aa
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- positive predicate support span
- end
- 2073
- end exclusive
- true
- exact text
- is indicated
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 2061
- qualifier mentions
- context exact
- symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn's disease (CD) who
- kind
- age
- polarity
- not_inferred
- span
- end
- 2174
- end exclusive
- true
- exact text
- adult patients
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 2160
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- source span
- end
- 2291
- end exclusive
- true
- exact text
- • reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn's disease (CD) who have had an inadequate response to conventional therapy.
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 2079
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22248ec8d1-8b3d-480f-8cdc-dbda1f130d17%22
- spl effective date
- 2026-07-28
- spl set id
- 37eaca10-d812-48bc-8b8e-b836bfa9968f
- spl version
- 24
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- non_oncology_or_unclear_candidate
Passage 21 · positive indication candidate
- application numbers
- BLA125544
- brand names
- INFLECTRA
- classification reasons
- inherited_predicate_from_same_label_section_requires_review
- no_tumor_directed_keyword_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 2638
- end exclusive
- true
- exact text
- gns and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn's disease (CD) who have had an inadequate response to conventional therapy. • reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing CD. 1.2 Pediatric Crohn's Disease INFLECTRA is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 2092
- current approval status
- not_reconciled
- duplicate text group
- dup-8a256a1205d8b7a53510
- extraction review status
- automated_candidate_pending_source_review
- generic names
- INFLIXIMAB-DYYB
- id
- ind-span-3c915dda2841be365d82
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- positive predicate support span
- end
- 2073
- end exclusive
- true
- exact text
- is indicated
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 2061
- qualifier mentions
- context exact
- nd rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing CD.
- kind
- age
- polarity
- not_inferred
- span
- end
- 2417
- end exclusive
- true
- exact text
- adult patients
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 2403
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- source span
- end
- 2438
- end exclusive
- true
- exact text
- • reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing CD.
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 2292
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22248ec8d1-8b3d-480f-8cdc-dbda1f130d17%22
- spl effective date
- 2026-07-28
- spl set id
- 37eaca10-d812-48bc-8b8e-b836bfa9968f
- spl version
- 24
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- non_oncology_or_unclear_candidate
Passage 22 · positive indication candidate
- application numbers
- BLA125544
- brand names
- INFLECTRA
- classification reasons
- explicit_positive_indication_predicate
- no_tumor_directed_keyword_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 2917
- end exclusive
- true
- exact text
- had an inadequate response to conventional therapy. • reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing CD. 1.2 Pediatric Crohn's Disease INFLECTRA is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active CD who have had an inadequate response to conventional therapy. 1.3 Ulcerative Colitis INFLECTRA is indicated for reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients wi
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 2239
- current approval status
- not_reconciled
- duplicate text group
- dup-73fd07fdb63bb948f35c
- extraction review status
- automated_candidate_pending_source_review
- generic names
- INFLIXIMAB-DYYB
- id
- ind-span-d0100d494c6a5aecf01c
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- positive predicate support span
- end
- 2491
- end exclusive
- true
- exact text
- is indicated
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 2479
- qualifier mentions
- context exact
- 1.2 Pediatric Crohn's Disease INFLECTRA is indicated for reducing signs a
- kind
- age
- polarity
- not_inferred
- span
- end
- 2452
- end exclusive
- true
- exact text
- Pediatric
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 2443
- context exact
- symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active
- kind
- age
- polarity
- not_inferred
- span
- end
- 2593
- end exclusive
- true
- exact text
- pediatric patients
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 2575
- context exact
- ng and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active CD who have ha
- kind
- age
- polarity
- not_inferred
- span
- end
- 2608
- end exclusive
- true
- exact text
- 6 years of age
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 2594
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- source span
- end
- 2717
- end exclusive
- true
- exact text
- 1.2 Pediatric Crohn's Disease INFLECTRA is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active CD who have had an inadequate response to conventional therapy.
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 2439
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22248ec8d1-8b3d-480f-8cdc-dbda1f130d17%22
- spl effective date
- 2026-07-28
- spl set id
- 37eaca10-d812-48bc-8b8e-b836bfa9968f
- spl version
- 24
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- non_oncology_or_unclear_candidate
Passage 23 · positive indication candidate
- application numbers
- BLA125544
- brand names
- INFLECTRA
- classification reasons
- explicit_positive_indication_predicate
- no_tumor_directed_keyword_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 3234
- end exclusive
- true
- exact text
- ptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active CD who have had an inadequate response to conventional therapy. 1.3 Ulcerative Colitis INFLECTRA is indicated for reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to conventional therapy. 1.4 Pediatric Ulcerative Colitis INFLECTRA is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 2518
- current approval status
- not_reconciled
- duplicate text group
- dup-f6d22f83bb4df897a46e
- extraction review status
- automated_candidate_pending_source_review
- generic names
- INFLIXIMAB-DYYB
- id
- ind-span-55fb555a6a642664b15a
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- positive predicate support span
- end
- 2763
- end exclusive
- true
- exact text
- is indicated
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 2751
- qualifier mentions
- context exact
- and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active ulcerative colitis (UC)
- kind
- age
- polarity
- not_inferred
- span
- end
- 2914
- end exclusive
- true
- exact text
- adult patients
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 2900
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- source span
- end
- 3034
- end exclusive
- true
- exact text
- 1.3 Ulcerative Colitis INFLECTRA is indicated for reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to conventional therapy.
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 2718
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22248ec8d1-8b3d-480f-8cdc-dbda1f130d17%22
- spl effective date
- 2026-07-28
- spl set id
- 37eaca10-d812-48bc-8b8e-b836bfa9968f
- spl version
- 24
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- non_oncology_or_unclear_candidate
Passage 24 · positive indication candidate
- application numbers
- BLA125544
- brand names
- INFLECTRA
- classification reasons
- explicit_positive_indication_predicate
- no_tumor_directed_keyword_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 3516
- end exclusive
- true
- exact text
- ssion and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to conventional therapy. 1.4 Pediatric Ulcerative Colitis INFLECTRA is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active UC who have had an inadequate response to conventional therapy. 1.5 Rheumatoid Arthritis INFLECTRA, in combination with methotrexate, is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 2835
- current approval status
- not_reconciled
- duplicate text group
- dup-9edd25e346cc82499d8f
- extraction review status
- automated_candidate_pending_source_review
- generic names
- INFLIXIMAB-DYYB
- id
- ind-span-0b4be4dd83d70d6a98c3
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- positive predicate support span
- end
- 3090
- end exclusive
- true
- exact text
- is indicated
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 3078
- qualifier mentions
- context exact
- 1.4 Pediatric Ulcerative Colitis INFLECTRA is indicated for reducing sign
- kind
- age
- polarity
- not_inferred
- span
- end
- 3048
- end exclusive
- true
- exact text
- Pediatric
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 3039
- context exact
- symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active
- kind
- age
- polarity
- not_inferred
- span
- end
- 3192
- end exclusive
- true
- exact text
- pediatric patients
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 3174
- context exact
- ng and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active UC who have ha
- kind
- age
- polarity
- not_inferred
- span
- end
- 3207
- end exclusive
- true
- exact text
- 6 years of age
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 3193
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- source span
- end
- 3316
- end exclusive
- true
- exact text
- 1.4 Pediatric Ulcerative Colitis INFLECTRA is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active UC who have had an inadequate response to conventional therapy.
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 3035
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22248ec8d1-8b3d-480f-8cdc-dbda1f130d17%22
- spl effective date
- 2026-07-28
- spl set id
- 37eaca10-d812-48bc-8b8e-b836bfa9968f
- spl version
- 24
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- non_oncology_or_unclear_candidate
Passage 25 · positive indication candidate
- application numbers
- BLA125544
- brand names
- INFLECTRA
- classification reasons
- explicit_positive_indication_predicate
- no_tumor_directed_keyword_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 3793
- end exclusive
- true
- exact text
- ptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active UC who have had an inadequate response to conventional therapy. 1.5 Rheumatoid Arthritis INFLECTRA, in combination with methotrexate, is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis (RA). 1.6 Ankylosing Spondylitis INFLECTRA is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis (AS). 1.7 Psoriatic Arthritis INFLECTRA is indicated for reducin
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 3117
- current approval status
- not_reconciled
- duplicate text group
- dup-898d1b6b1b3e87697500
- extraction review status
- automated_candidate_pending_source_review
- generic names
- INFLIXIMAB-DYYB
- id
- ind-span-d15855ce27452249e3f1
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- positive predicate support span
- end
- 3399
- end exclusive
- true
- exact text
- is indicated
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 3387
- qualifier mentions
- context exact
- on of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis (RA
- kind
- age
- polarity
- not_inferred
- span
- end
- 3531
- end exclusive
- true
- exact text
- adult patients
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 3517
- context exact
- 1.5 Rheumatoid Arthritis INFLECTRA, in combination with methotrexate, is indicated for reducing signs and symptoms, inhibiting t
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 3385
- end exclusive
- true
- exact text
- methotrexate
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 3373
- context exact
- 1.5 Rheumatoid Arthritis INFLECTRA, in combination with methotrexate, is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis (RA)
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 3532
- end exclusive
- true
- exact text
- in combination with methotrexate, is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 3353
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- source span
- end
- 3593
- end exclusive
- true
- exact text
- 1.5 Rheumatoid Arthritis INFLECTRA, in combination with methotrexate, is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis (RA).
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 3317
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22248ec8d1-8b3d-480f-8cdc-dbda1f130d17%22
- spl effective date
- 2026-07-28
- spl set id
- 37eaca10-d812-48bc-8b8e-b836bfa9968f
- spl version
- 24
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- non_oncology_or_unclear_candidate
Passage 26 · positive indication candidate
- application numbers
- BLA125544
- brand names
- INFLECTRA
- classification reasons
- explicit_positive_indication_predicate
- no_tumor_directed_keyword_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 3934
- end exclusive
- true
- exact text
- cated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis (RA). 1.6 Ankylosing Spondylitis INFLECTRA is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis (AS). 1.7 Psoriatic Arthritis INFLECTRA is indicated for reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in adult patients
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 3394
- current approval status
- not_reconciled
- duplicate text group
- dup-fef2ba5100605fa46459
- extraction review status
- automated_candidate_pending_source_review
- generic names
- INFLIXIMAB-DYYB
- id
- ind-span-dde6fe25d6e95fd89764
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- positive predicate support span
- end
- 3643
- end exclusive
- true
- exact text
- is indicated
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 3631
- qualifier mentions
- context exact
- s INFLECTRA is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis (AS).
- kind
- age
- polarity
- not_inferred
- span
- end
- 3693
- end exclusive
- true
- exact text
- adult patients
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 3679
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- source span
- end
- 3734
- end exclusive
- true
- exact text
- 1.6 Ankylosing Spondylitis INFLECTRA is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis (AS).
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 3594
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22248ec8d1-8b3d-480f-8cdc-dbda1f130d17%22
- spl effective date
- 2026-07-28
- spl set id
- 37eaca10-d812-48bc-8b8e-b836bfa9968f
- spl version
- 24
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- non_oncology_or_unclear_candidate
Passage 27 · positive indication candidate
- application numbers
- BLA125544
- brand names
- INFLECTRA
- classification reasons
- explicit_positive_indication_predicate
- no_tumor_directed_keyword_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 4165
- end exclusive
- true
- exact text
- h moderately to severely active rheumatoid arthritis (RA). 1.6 Ankylosing Spondylitis INFLECTRA is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis (AS). 1.7 Psoriatic Arthritis INFLECTRA is indicated for reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in adult patients with psoriatic arthritis (PsA). 1.8 Plaque Psoriasis INFLECTRA is indicated for the treatment of adult patients with chronic severe (i.e., extensive and/or disabling) plaque psoriasis (Ps) who are candidates for systemic therapy an
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 3535
- current approval status
- not_reconciled
- duplicate text group
- dup-19329d3e45cc9f02618a
- extraction review status
- automated_candidate_pending_source_review
- generic names
- INFLIXIMAB-DYYB
- id
- ind-span-9fd871055c3af1d5a7e9
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- positive predicate support span
- end
- 3781
- end exclusive
- true
- exact text
- is indicated
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 3769
- qualifier mentions
- context exact
- on of structural damage, and improving physical function in adult patients with psoriatic arthritis (PsA).
- kind
- age
- polarity
- not_inferred
- span
- end
- 3933
- end exclusive
- true
- exact text
- adult patients
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 3919
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- source span
- end
- 3965
- end exclusive
- true
- exact text
- 1.7 Psoriatic Arthritis INFLECTRA is indicated for reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in adult patients with psoriatic arthritis (PsA).
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 3735
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22248ec8d1-8b3d-480f-8cdc-dbda1f130d17%22
- spl effective date
- 2026-07-28
- spl set id
- 37eaca10-d812-48bc-8b8e-b836bfa9968f
- spl version
- 24
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- non_oncology_or_unclear_candidate
Passage 28 · positive indication candidate
- application numbers
- BLA125544
- brand names
- INFLECTRA
- classification reasons
- explicit_positive_indication_predicate
- no_tumor_directed_keyword_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 4413
- end exclusive
- true
- exact text
- RA is indicated for reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in adult patients with psoriatic arthritis (PsA). 1.8 Plaque Psoriasis INFLECTRA is indicated for the treatment of adult patients with chronic severe (i.e., extensive and/or disabling) plaque psoriasis (Ps) who are candidates for systemic therapy and when other systemic therapies are medically less appropriate. INFLECTRA should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician [see Boxed Warning , Warnings and Precautions (5) ] .
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 3766
- current approval status
- not_reconciled
- duplicate text group
- dup-5671ed157110fdc9a9ff
- extraction review status
- automated_candidate_pending_source_review
- generic names
- INFLIXIMAB-DYYB
- id
- ind-span-64218e1fb29542d54e1d
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- positive predicate support span
- end
- 4009
- end exclusive
- true
- exact text
- is indicated
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 3997
- qualifier mentions
- context exact
- laque Psoriasis INFLECTRA is indicated for the treatment of adult patients with chronic severe (i.e., extensive and/or disabling) plaq
- kind
- age
- polarity
- not_inferred
- span
- end
- 4045
- end exclusive
- true
- exact text
- adult patients
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 4031
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- source span
- end
- 4228
- end exclusive
- true
- exact text
- 1.8 Plaque Psoriasis INFLECTRA is indicated for the treatment of adult patients with chronic severe (i.e., extensive and/or disabling) plaque psoriasis (Ps) who are candidates for systemic therapy and when other systemic therapies are medically less appropriate.
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 3966
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22248ec8d1-8b3d-480f-8cdc-dbda1f130d17%22
- spl effective date
- 2026-07-28
- spl set id
- 37eaca10-d812-48bc-8b8e-b836bfa9968f
- spl version
- 24
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- non_oncology_or_unclear_candidate
Passage 29 · risk or warning
- application numbers
- BLA125544
- brand names
- INFLECTRA
- classification reasons
- risk_or_warning_words_without_positive_predicate
- clinical review status
- pending
- content role
- risk_or_warning
- context span
- end
- 4413
- end exclusive
- true
- exact text
- f adult patients with chronic severe (i.e., extensive and/or disabling) plaque psoriasis (Ps) who are candidates for systemic therapy and when other systemic therapies are medically less appropriate. INFLECTRA should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician [see Boxed Warning , Warnings and Precautions (5) ] .
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 4029
- current approval status
- not_reconciled
- duplicate text group
- dup-50076dba2033815dda1b
- extraction review status
- automated_candidate_pending_source_review
- generic names
- INFLIXIMAB-DYYB
- id
- ind-span-c8103ff5fa406c32f01e
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source defined aliases
- source span
- end
- 4413
- end exclusive
- true
- exact text
- INFLECTRA should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician [see Boxed Warning , Warnings and Precautions (5) ] .
- label id
- 248ec8d1-8b3d-480f-8cdc-dbda1f130d17
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 3971dff22db8a96f1f35e3655fea0006468bae46e5c4aa7d1fe5e3e2634fb4a5
- start
- 4229
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22248ec8d1-8b3d-480f-8cdc-dbda1f130d17%22
- spl effective date
- 2026-07-28
- spl set id
- 37eaca10-d812-48bc-8b8e-b836bfa9968f
- spl version
- 24
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- not_applicable
Preserved source evidence · Not medical advice